On the horizon

All cell lines that feature in this section have not currently gone through the banking process and therefore have not passed any Quality Control testing. Availability of these lines will only be possible once they have been processed through our Banking Procedures and have completed all Quality Control testing.

To register that you are interested in any of the below cell lines please submit a technical enquiry stating which cell lines you are interested in.

See our new cell lines

 

Mouse Fibrosarcoma Cell Line Collection

A collection of 8 Mouse fibrosarcoma cell lines, deposited by Ximbio, which are capable of expressing all vascular endothelial growth factor (VEGF) isoforms (known as the Control cell lines) or only single isoforms of VEGF (VEGF120, VEG164, or VEG188). These were developed under endogenous VEGF promotor control.

Vascular endothelial growth factor-A (VEGF) is produced in multiple isoforms by most cancer cells, which display distinct biological activities. VEGF plays an undisputed role in tumour growth, vascularisation and metastasis. The detailed functions of individual isoforms in these processes remain poorly understood. The research group led by Gillian Tozer at the Tumour Microcirculation Group, Department of Oncology and Metabolism, University of Sheffield Schoolm United Kingdom, have investigated the effects of three main murine isoforms (VEGF120, 164 and 188) on tumour cell behaviour, using a panel of fibrosarcoma cells they developed that express each isoform individually under the control of their endogenous promotor control. These cell lines are deposited within the ECACC General Collection by Ximbio.

Cells are available in a non-fluroscent and fluorescent form, with the latter expressing Luciferase2 and mStrawberry to allow optical imaging of tumour deposits.

Catalogue Number	Cell Line Name
17100507	Mouse fibrosarcoma VEGFWT (Control)
17100508	Mouse fibrosarcoma VEGF188
17100509	Mouse fibrosarcoma VEGF120
17100510	Mouse fibrosarcoma VEGF164
17100518	Mouse fibrosarcoma Luciferase2 mStrawberry VEGFWT (Control)
17100526	Mouse fibrosarcoma Luciferase2 mStrawberry VEGF120
17100527	Mouse fibrosarcoma Luciferase2 mStrawberry VEGF164
17100528	Mouse fibrosarcoma Luciferase2 mStrawberry VEGF188

 

HCT 116 Derivatives 

Recent studies by the Drug Resistance Group, Queen's University Belfast, has shown that anticancer drugscan trigger the activation of human epidermal receptor (HER) survival pathways in colorectal cancer (CRC). Chemotherapy (5-fluorouracil) treatment has been shown to result in acute increase in transforming growth factor-α, amphiregulin, and heregulin ligand shedding in vitro and in vivo correlating with significantly increased ADAM-17 activity. ADAMs (a desintergrin and metalloproteases family), specifically ADAM-17 is involved in regulating HER1 activation.

The cell line HTC 116 ADAM17, deposited by Ximbio, was developed to stably overexpress HA-tagged ADAM-17. Western blot analysis identified TGF-α, AREG and heregulin shredding and an increase in EGFR and HER3 activation compared to the empty vector control line.

Catalogue Number	Cell Line Name
17031402	HCT 166  ADAM17

 

ALX is a member of the TAM (Tyro3, AXL and MER) receptor tyrosine kinase family. It is ubiquitously expressed and detected in a wide variety of cells and has been reported in a wide variety of cancers. Receptor tyrosine kinase (RTK) screens identified AXL as a protein which underpins the migratory/invasive phenotype in colorectal cancer (CRC). AXL was shown to be a poor prognostic marker and an important mediator of cell migration/invasiveness. HCT 116 AXL KO Tet-inducible cell line, deposited by Ximbio, enables further investigation into the target as a prognostic biomarker and therapeutic target.

Catalogue Number	Cell Line Name
17031404	HCT 116 AXL Tet-inducible

 

EphA2 (Eph receptor tyrosine kinase family) is an important regulator of tumour initation, neo-vascularisation and metastasis in a range of epithelial and mesenchymal cancers. It has structural homology and affinity for binding the GPI-anchored Ephrin-A.

The HCT 116 EphA2 KO Tet-inducible cell line, deposited by Ximbio, was developed to address the involvement of EphA2 where it was shown that silencing of the protein suppressed migration and invasion. EphA2 is overexpressed in invasive colorectal cancer and correlates with increased expression of stem cell marker CD44. Expression levels are regulated by KRAS through the MAPK and RalGDS-RalA pathways.

Catalogue Number	Cell Line Name
17031406	HCT 116 EphA2 KO Tet-inducible

 

The Epithelial-Mesenchymal transition (EMT) has been suggested to play a role in the initial invasion step during cancer metastasis.

The HCT 116-I6 Invasive cell line, deposited by Ximbio, is a sub-line of HCT 116 that demonstrates a 4- and 20-fold increase in migration and invasion rate respectively, compared to the parental HCT 116 cell line. The increased migratory/invasion capacity seen in HCT 116-I6 cells is a stable event and not due to increased proliferation rates. In contrast to the parental line, the HCT 116-I6 Invasive cell line has transitioned to a spindle-shaped mesenchymal-like morphology. In keeping with the changes observed in EMT, a loss of E-cadherin (a well-known epithelial marker) and a gain of mesenchymal marker SNAIL was observed. CD44 expression was found to be 4-fold higher. There was a decreased level of TGF-α and amphiregulin with a decreased basal activity of EGFR, HER2 and IGF-IR.

Catalogue Number	Cell Line Name
17031408	HCT 116-I6 Invasive

 

Babraham Institute Cell Lines

HM3 cells are HEK 293 cells stably expressing conditional kinase ΔMEKK3:ER* from the pBabePuro plasmid. ΔMEKK3:ER* consists of the isolated kinase domain of MEKK3 fused in-frame to a modified form of the hormone binding domain of the oestrogen receptor (hbER*) that can be de-repressed by 4-hydroxytamoxifen (4-HT) but not β-estradiol. In this case, the * refers to a point mutation that ablates estradiol binding but allows 4-HT binding.

Activation of the ΔMEKK3:ER* leads to the strong activation of the JNK and p38 pathways and a weaker activation of ERK1/2. This cell line, deposited by Ximbio, can be used to study the role and factors impacting on the JNK, p38 and ERK1/2 signalling pathways such as gene expression, cell proliferation, cell cycle arrest and cell death. The cells are puromycin resistant. Conditional kinase activation of ΔMEKK3:ER* can be induced with 100nM 4-HT.

Catalogue Number	Cell Line Name
17031410	HM3

 

HR1 cells are HEK 293 cells stably expressing conditional kinase ΔRaf-1:ER* from the pCMV Neo Myc plasmid. ΔRaf-1:ER* (also known as ΔCRAF:ER*) consists of the isolated kinase domain of c-Raf1 fused in-frame to a modified form of the hormone binding domain of the oestrogen receptor (hbER*) that can be de-repressed by 4-hydroxytamoxifen (4-HT) but not β-estradiol. In this case the * refers to a point mutation that ablates estradiol binding but allows 4-HT binding.

Activation of ΔRaf-1:ER* leads to the selective activation of the ERK1/2 pathway. This cell line, deposited by Ximbio, can be used to study the cellular role and factors impacting on the ERK1/2 signalling pathway such as gene expression, cell proliferation, cell cycle arrest and cell death. The cells are G418 resistant. Conditional kinase activation of ΔRaf-1:ER* can be induced with 100nM of 4-HT.

Catalogue Number	Cell Line Name
17031412	HR1

 

Cancer Research UK Glasgow – The Beatson Institute

Fumarate hydratase - which can be found in either a mitochondrial or cytosolic form - is an enzyme that catalyses the reversible hydration and dehydration of fumarate to malate. Signal sequences located in the protein dictate the subcellular location of each FH isoenzyme. The cytosolic form is involved in the metabolism of amino acids and fumarate and the mitochondrial form is involved in the Krebs Cycle (tricarboxylic acid cycle or the citric acid cycle). Germline mutations of FH are responsible for hereditary leiomyomatosis and renal-cell cancer (HLRCC)1.

FH fl/fl is a conditional knock-out model in which the deletion of fumarate hydratase can be achieved by intracellular expression of Cre recombinase. FH -/- CL1 and FH -/- CL19 cell lines are Knock-out models. All three lines were developed from Mouse kidney tissue and deposited into the collection by Ximbio.

Catalogue Number	Cell Line Name
17100519	FH fl/fl
17100520	FH -/- CL1
17100521	FH -/- CL19

 

Succinate dehydrogenase (SDH) is a enzyme complex found in the inner mitrochondrial membrane of mammalian mitochondria and many bacterial cells. SDH is the only enzyme that participates in both the electron transport chain and citric acid cycle. The enzymatic function of SDH oxidises succinate to fumarate in the tricarboxylic acid cycle and losing this function is associated with cancer formation.

SDH fl/fl is a conditional knock-out model in which the deletion of succinate dehydrogenase can be achieved by intracellular expression of Cre recombinase. SDH -/- CL5 and SDH -/- CL7 cell lines are Knock-out models. All three lines were developed from Mouse kidney tissue and deposited into the collection by Ximbio.

Catalogue Number	Cell Line Name
17100522	SDH fl/fl
17100523	SDH -/- CL5
17100524	SDH -/- CL7

 

Cancer Research UK London Research Institute: Lincoln's Inn Fields

 The Gamma2A Jak2 cell line, deposited by Ximbio, has been developed by expressing protein tyrosine kinase JAK2 in a mutant cell line defective in the interferon-gamma signal transduction pathway. By using this cell line, the structural and functional analysis of JAK2 in IFN-gamma signalling has been examined. The cell line revealed that the specificity of JAK may lie mainly in their structural ineraction with different receptors and signalling proteins rather than in the substrate specificity of their kinase domains.

Catalogue Number	Cell Line Name
17011203	Gamma2A Jak2 Cell Line

The E3 cell line, deposited by Ximbio, is an immortalised Mouse mammary cell line which was developed to examine the possibility of using the MUC1 gene and its products in active immunisation against breast and other carcinomas. The human MUC1 gene codes for a type I membrane glycoprotein that is normally expressed on the apical surface of most glandular epithelial cell, but which is upregulated and under- or differently glycosylated in carcinomas; these differences in glycosylation lead to the exposure of novel epitopes which are not found on the normally processed mucin and can therefore be used as targets.

In addition to this a further cell line was developed; E2 STn, a mouse mammary carcinoma cell line E3 which expresses human MUC1 and Sialyl-Tn. Changes in the composition of glycans added to glycoproteins and glycolipids are characteristic of the change to malignancy. Sialyn-Tn (STn) is expressed by 25-20% of breast carcinomas but its expression on normal tissue is highly restricted. Sialyl-Tn is an O-linked disaccharide that can be carried on various glycoproteins. One such glycoprotein MUC1 is expressed by the vast majority of breast carcinomas. Both STn and MUC1 have been considered targets for immunotherapy of breast cancer patients.

Catalogue Number	Cell Line Name
17011204	E3 Cell Line
17011205	E3 STn Cell Line

The CHO ICAM-1Fc cell line, deposited by Ximbio, was developed from the parental Chinese Hamster Ovary (CHO) and is a transgenic model. CHO ICAM-1Fc cells secrete a dimeric human ICAM-1Fc protein. ICAM-1 (CD54) is a major ligand for leukocyte CD11/CD18 integrins and used in adhesion assays to evaluate integrin activity.

Human ICAM-1Fc chimeric protein (five extracellular domains of ICAM-1 plus hinge, CH2 and CH3 domains of IgG1) is the protein target related to this cell line.

Catalogue Number	Cell Line Name
17011208	CHO ICAM-1Fc Cell Line

 

King's College London

The parental T47D cell line, deposited by Ximbio, was estabilished from the pleural effusion of a ductal carcinoma of the breast. The tumour cell line, T47D-E2J, was created as a breast cancer model with an O-linked glycosylation profile similar to normal mammary epithelial cells. T47D-E2J cells overexpress the enzyme C2GnT1, a beta-1,3-galactosyl-O-glycosyl-glycoprotein.

C2GnT1 is the dominant enzyme expressed in normal breast tissue known to convert core 1 glycoproteins to core 2 glycoproteins, by the addition of N-acetylglucosamine to N-acetylgalactosamine. Expression of the C2GnT1 enzyme has been found to be decreased or absent in most breast cancer cell lines despite still expressing mRNAs coding for this enzyme.

The tumour cell line, T47D-STn, was created as a breast cancer model which expresses the Sialyl-Tn, STn, antigen. These cells overexpress the enzymes C2GnT1,  a beta-1,3-galactosyl-O-glycosyl-glycoprotein and glycosyltransferase, ST6GalNAc-I. ST6GalNAc-I which is found throughout the Golgi, can catalyse the transfer of sialic acid to N-acetylgalactosamine and is predominately limited to the gastrointestinal tract in normal adult tissues. Expression of ST6GalNAc-I in human cells promotes formation of the STn antigen which is a saccharide structure (N-acetylgalactosamine) lines to serine or threonine by a glycosidic bond. STn antigens are not usually found on health cell surfaces but often on human breast cancer cells. 

 17011207

T47D-E2J Cell Line 

Catalogue Number	Cell Line Name
17011206	T47D-E2J Cell Line

 

University of Dundee

The U-2 OS Gal4-p300 cell line, deposited by Ximbio, is a human Osteosarcoma cell line developed by the University of Dundee. U2-OS cells expressing Gal4-p300, a transcriptional coactivator that functions as an integrator of numerous signalling pathways is utilised by many DNA binding proteins to facilitate transcriptional activation. p300 shares numerous conserved domains with CREB binding protein (CBP), which is also a transcriptional coactivator. These shared domains include a histone acetyl transferase (HAT) domain, a bromo domain, and three cysteine- and histidine-rich domains. CBP also interacts with the RNA polymerase II holoenzyme and p300/CBP both contain transcriptional activation domains that function independently of HAT activity.

Catalogue Number	Cell Line Name
17011202	U-2 OS Gal4-p300

 

Miami Cell Lines

Human Ovarian Cancer Cell Line Collection

The U-2 OS Gal4-p300 cell A new set of 15 ovarian cancer cell lines are being accessioned into the ECACC General Cell Collection. These new lines have been characterised to ensure the genomic landscape, histopathology and molecular features of the original tumours is maintained. The new collection is a valuable resource for the study of ovarian cancers and therapeutic development for their treatment, providing a greatly improved platform for in vitro and xenograft based investigations into high-grade, poorly differentiated ovarian cancers. Clear cell, Serous, Mullerian, Endometrioid, Carcinosarcoma and Mucinous tumour histologies are represented along with p53, PI3K and BRCA2 mutants identified.

Catalogue Number	Cell Line Name
20012001	OCI-C1p
20012002	OCI-C4p
20012003	OCI-C5x
20012004	OCI-P2a
20012005	OCI-P5x
20012006	OCI-P7a
20012007	OCI-P8p
20012008	OCI-P9a1
20012009	FCI-P2p
20012010	OCI-CSp
20012011	OCI-U1a
20012012	OCI-E1p
20012013	OCI-EP1p
20012014	OCI-M1p
20012015	OCI-P9a2

 

Ovarian and Fallopian Tube Cell Line Collection

Cells from the ovarian and fallopian tube cell lines were harvested from two post-menopausal female doctors aged 56 and 65, respectively, during surgical treatment for benign gynaecological conditions. These cell lines display evidence of increased resistance to Cisplatin and Taxol when compared to standard ovarian cancer lines, which suggests that in vitro drug responses of these lines correlate closely with in vivo patient responses. These cell lines are offered as an immortalised 'normal' line (OCE1, OCE2, FNE1, FNE2), a transformed line (OCLE1, OCLE2, FNLE1, FNLE2), and a tumourigenic line (OCLER1, OCLER2, FNLER1, FNLER2). The OCE cell line is consistent with ovarian surface/inclusion cyst epithelium while FNE cells are similar to those of non-cilliated epithelium found in the fallopian tube in mouse xenograft models when compared to normal human ovaries and fallopian tubes.

Catalogue Number	Cell Line Name
20012016	OCE1
20012017	OCLE1
20012018	OCLER1
20012019	OCE2
20012020	OCLE2
20012021	FNLER2
20012022	FNE1
20012023	FNLE1
20012024	FNLER1
20012025	FNE2
20012026	FNLE2

 

Breast Epithelial Cell Line Collection

Breast Epithelial cell lines were established from patients who underwent disease free reduction mammoplasties and were aged between 26 and 48 years old. These cell lines were derived from the same originating patients and are offered as immortalised 'normal' line (BPE1, BPE2, BPE3, BPE4 and HME2, HME3, HME4), a transformed line (BPLE1, BPLE2, BPLE3, BPLE4 and HMLE2, HMLE3, HMLE4), and a tumourigenic line (BPLER1, BPLER2, BPLER3, BPLER4 and HMLER2, HMLER3, HMLER4). The gene expression vectors were sequentially introduced to recipient cells in individual steps in the following order: pmig-GFP-hTERT expressing cells relative to their corresponding normal cell type.

Catalogue Number	Cell Line Name
20012027	BPE1
20012028	BPLE1
20012029	BPLER1
20012030	BPE2
20012031	BPLE2
20012032	BPLER2
20012033	BPE3
20012034	BPLE3
20012035	BPLER3
20012038	BPLER4
20012039	HME2
20012040	HMLE2
20012041	HMLER2
20012042	HME3
20012043	HMLE3
20012044	HMLER3
20012045	HME4
20012046	HMLE4
20091601	HMLER4

 

Dublin City University Collection

A number of cancerous, drug resistant cell lines have been deposited by Dublin City University.

The DLKP family of cells are taken from a poorly differentiated lung squamous cell carcinoma, established from a lymph node biopsy of a 52-year-old male. Several sub-populations of this cell line will be available in our General Cell Collection (Acc Nos. 20082601-20082604), with various lines showing tumourigenicity in SCID-Mice strain CB17/Icr-Prkdcscid. A number of these lines are Adriamycin-resistant (Acc Nos. 20082607-20082609 and 20091601) and Mitoxantrone-resistant (Acc Nos. 20082605-20082606).

They have also deposited some drug resistant variants of the SK MES 1 cell line, a Human Caucasian lung squamous carcinoma, with us. These lines show resistance to Taxotere and Adriamycin. The final cell line is an Adriamycin-resistant variant of OAW42, a human ovarian tumour derived from an ascites of a patient with ovarian cystadenocarcinoma (Acc No. 20082613).

Catalogue Number	Cell Line Name
20082601	DLKP
20082602	DLKP-I
20082603	DLKP-M
20082604	DLKP-SQ
20082605	DLKP-SQ-Mitotox-BCRP
20082606	DLKP-SQ-Mitotox-MDR
20082607	DLKP-A
20082608	DLKP-A5F
20082609	DLKP-A10F
20082610	DLRP
20082611	SKMES-1-A
20082612	SKMES-1-Txt
20082613	OAW42-A
20091601	DLKP pHaMDR/A

 

Unite du Virologie et Immunologie Moléculaires, Institut National de la Recherche Agronomique (INRAE), France

The Molecular Virology and Immunology Unit, National Institute of Agronomic Research in France, alongside the Aquatic and Fish Health, Marine Scotland, Aberdeen, Scotland, UK have deposited a Chinook Salmon (Oncorhynchus tshawytscha) cell line into our General Cell Collection. This genetically modified cell line is derived from CHSE-214 (Acc No. 91041114); and permanently expresses a monomeric form of the Enhanced Green Fluorescent Protein (mEGFP) and is resistant to G418. It is susceptible to a wide range of fish viruses and in many instances, replicates high titres.

Catalogue Number	Cell Line Name
20090901	CHSE-E

 

Translational and Clinical Research Institute, Newcastle University, UK

The AR42J-B13 cell is a readily expandable rat pancreatic acinar-like cell that differentiates on simple plastic culture substrata into replicatively-senescent hepatocyte-like (B-13/H) cells in response to glucocorticoid exposure. B-13/H cells express a variety of liver-enriched and liver-specific genes, main at levels similar to hepatocytes in vivo. Furthermore, the B-13/H phenotype is maintained for at least several weeks in vitro, in contrast to normal hepatocytes which rapidly de-differentiate under the same simple- or even more complex- culture conditions. These cells will provide an unlimited supply of hepatocyte-like cells for liver and toxicology studies.

Catalogue Number	Cell Line Name
20100101	AR42J-B13